Chidamide
6 clinical trials
7 abstracts
8 indications
Indication
acute myeloid leukemiaIndication
Acute Myeloid LeukemiaIndication
Acute Monocytic LeukemiaIndication
Newly DiagnosedIndication
Peripheral T Cell LymphomaIndication
Epigenetic RepressionIndication
Diffuse Large B-Cell LymphomaIndication
Colorectal CancerClinical trial
A Multicenter, Randomized, Controlled Clinical Trial of Chidamide Combined With Venetoclax and Azacitidine in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) Who Are Not Suitable for Intensive ChemotherapyStatus: Not yet recruiting, Estimated PCD: 2027-12-30
Abstract
Efficacy and safety of chidamide in combination with serplulimab and standard third-line treatments in advanced colorectal cancer: A single arm, exploratory phase 2 trial.Org: The First Affiliated Hospital of Suzhou University, Suzhou, China, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, The First Affiliated Hospital of Soochow University,
Abstract
Dalpiciclib and chidamide in patients with HR+/HER2- advanced breast cancer and resistance to CDK4/6 inhibitors: A phase Ib trial.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China,
Abstract
Phase I trial of chidamide, an oral HDAC inhibitor, in combination with oral etoposide in patients with refractory/recurrent neuroblastoma.Org: Yuexiu District, Guangzhou,
Abstract
Rituximab, chidamide, and zanubrutinib (ZCR) ± CHOP as a regimen for treatment naive (TN) double-expressor DLBCL (DE-DLBCL).Org: Affiliated Dongguan People’s Hospital, Dongguan People’s Hospital,
Clinical trial
A Multicenter, Randomized, Controlled Clinical Trial of Venetoclax, Azacytidine Combined With Chidamide for the Treatment of Newly Diagnosed Acute Monocytic Leukemia Patients That Are Ineligible for Intensive ChemotherapyStatus: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
Randomized Study of ABC-14 Regimen ( AZA, Venetoclax and Chidamide) Compared With "3+7" Standard Induction Therapy or AB-14 (Venetoclax Combined With Azacitidine) for Newly Diagnosed Acute Myeloid LeukemiaStatus: Not yet recruiting, Estimated PCD: 2026-12-30
Clinical trial
Chidamide Plus Azacitidine Epigenetic Repression for the Treatment of Previously Untreated Nodal T-follicular Helper (TFH) Cell LymphomaStatus: Recruiting, Estimated PCD: 2026-03-02
Clinical trial
A Phase 2 Study of Chidamide, Azacitidine Combined With GM Regimen for Patients With Relapsed and Refractory DLBCLStatus: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
A Randomized Phase 2 Clinical Trial Evaluating Sintilimab and Chidamide in Combination With or Without IBI305 in Patients With Standard Treatment Failure of Advanced or Metastatic pMMR/MSS Colorectal CarcinomaStatus: Active (not recruiting), Estimated PCD: 2022-07-26
Abstract
A phase II clinical trial of chidamide in combination with toripalimab in patients with advanced soft tissue sarcoma.Org: Department of Medical Melanoma and Sarcoma, Sun Yat-sen University Cancer Center Gansu Hospital, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Collaborative Innovation Center for Cancer Medicine, Melanoma and Sarcoma Medical Oncology Unit, Sun Yat-sen University Cancer Center, Guangzhou, China,
Abstract
First-line HDACi plus tislelizumab combined with chemotherapy in advanced NSCLC.Org: The Fifth Medical Center of PLA General Hospital, Beijing, China, Department of medical oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China, School of Medicine, Nankai University, Tianjin, China, The First Medical Center of PLA General Hospital, Beijing, China, School of Medicine, Nankai University, Beijing, China,
Abstract
Multicenter real-world study of newly diagnosed advanced-stage extranodal natural killer/T-cell lymphoma (ENKTL): Proposal for intensive therapy.Org: National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, China, Beijing, China, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, WA, China, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, China, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, China, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China,